[go: up one dir, main page]

ECSP21080740A - Inhibidores del inflamasoma nlrp3 - Google Patents

Inhibidores del inflamasoma nlrp3

Info

Publication number
ECSP21080740A
ECSP21080740A ECSENADI202180740A ECDI202180740A ECSP21080740A EC SP21080740 A ECSP21080740 A EC SP21080740A EC SENADI202180740 A ECSENADI202180740 A EC SENADI202180740A EC DI202180740 A ECDI202180740 A EC DI202180740A EC SP21080740 A ECSP21080740 A EC SP21080740A
Authority
EC
Ecuador
Prior art keywords
nlrp3
inhibitors
inflamasome
nlrp3 inflamasome
relates
Prior art date
Application number
ECSENADI202180740A
Other languages
English (en)
Inventor
Christopher Farady
Eric Vangrevelinghe
Juraj Velcicky
Henri Mattes
Solovay Catherine Fooks
Nichola Smith
Philipp Janser
Matt Anette Von
Nikolaus Johannes Stiefl
Nina Gommermann
Angela Mackay
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP21080740A publication Critical patent/ECSP21080740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de piridazin-3-il fenol de la Fórmula (I): (I), en donde R1, R2, R3, R4, R5 y Z están definidos en la presente, que inhiben la actividad del inflamasoma de la proteína 3 del receptor tipo NOD (NLRP3). La invención además se refiere a procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y a su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.
ECSENADI202180740A 2019-05-17 2021-11-15 Inhibidores del inflamasoma nlrp3 ECSP21080740A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962849245P 2019-05-17 2019-05-17

Publications (1)

Publication Number Publication Date
ECSP21080740A true ECSP21080740A (es) 2021-12-30

Family

ID=70779818

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180740A ECSP21080740A (es) 2019-05-17 2021-11-15 Inhibidores del inflamasoma nlrp3

Country Status (26)

Country Link
US (4) US11208399B2 (es)
EP (1) EP3969441A1 (es)
JP (2) JP7558975B2 (es)
CN (2) CN119732956A (es)
AR (1) AR119731A1 (es)
AU (1) AU2020277738B2 (es)
BR (1) BR112021022796A2 (es)
CA (1) CA3138226A1 (es)
CL (1) CL2021003012A1 (es)
CO (1) CO2021015030A2 (es)
CR (1) CR20210552A (es)
CU (1) CU20210094A7 (es)
DO (1) DOP2021000228A (es)
EC (1) ECSP21080740A (es)
IL (1) IL287042B2 (es)
JO (1) JOP20210307A1 (es)
MX (1) MX2021013941A (es)
MY (1) MY206068A (es)
PE (1) PE20220133A1 (es)
PH (1) PH12021552885A1 (es)
SA (1) SA521430853B1 (es)
SG (1) SG11202111029PA (es)
TW (1) TWI874398B (es)
UY (1) UY38687A (es)
WO (1) WO2020234715A1 (es)
ZA (1) ZA202107444B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
AR121669A1 (es) 2020-03-27 2022-06-29 Astellas Pharma Inc Compuesto de piridazina sustituida
JP2023546199A (ja) * 2020-10-20 2023-11-01 サノフイ アシアロ糖タンパク質受容体のための新規リガンド
CN116507608A (zh) * 2020-11-20 2023-07-28 戴纳立制药公司 化合物、组合物和方法
US20240391895A1 (en) * 2020-12-25 2024-11-28 Tuojie Biotech (Shanghai) Co., Ltd. Pyridazine-containing compound and medicinal use thereof
CN116867769A (zh) * 2021-02-08 2023-10-10 南京明德新药研发有限公司 取代的哒嗪苯酚类衍生物
CN117083272A (zh) 2021-03-04 2023-11-17 詹森药业有限公司 调节nlrp3的4-烷氧基-6-氧代-哒嗪衍生物
JP2024508010A (ja) * 2021-03-04 2024-02-21 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３を調節する４－アミノ－６－オキソ－ピリダジン誘導体
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
EP4345097A4 (en) 2021-04-28 2025-04-23 Astellas Pharma Inc. SUBSTITUTED TRIAZINE COMPOUND
BR112023023527A2 (pt) 2021-05-12 2024-01-30 Hoffmann La Roche Inibidores de nlrp3
IL307201A (en) * 2021-06-04 2023-11-01 Hoffmann La Roche Triazine derivatives and their use in cancer treatment.
US20240294542A1 (en) * 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
JP2024529839A (ja) * 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
US11970463B2 (en) 2021-07-02 2024-04-30 Astrazeneca Ab Compounds and their use
EP4375274A4 (en) 2021-07-21 2025-08-06 Nico Therapeutics Inc RINGED PYRIDAZINE COMPOUND
PE20241727A1 (es) 2021-08-25 2024-08-19 Ptc Therapeutics Inc Inhibidores de nlrp3
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
CN115417856B (zh) * 2021-09-30 2025-06-27 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
US20250002470A1 (en) 2021-10-22 2025-01-02 Zhejiang Aixplorer Biotech Co., Ltd. Nitrogen-containing compound, preparation method therefor and application thereof
KR20230066899A (ko) 2021-11-08 2023-05-16 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
CN118234730A (zh) * 2021-11-17 2024-06-21 豪夫迈·罗氏有限公司 杂环nlrp3抑制剂
EP4433459A1 (en) 2021-11-19 2024-09-25 F. Hoffmann-La Roche AG Pyridazine derivatives as inhibitors of nlrp3
US20250074888A1 (en) * 2021-12-29 2025-03-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
TW202327604A (zh) * 2022-01-07 2023-07-16 大陸商藥捷安康(南京)科技股份有限公司 Ｎｌｒｐ３發炎小體抑制劑及其應用
AU2023238121A1 (en) * 2022-03-25 2024-10-10 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives
EP4499646A1 (en) * 2022-03-31 2025-02-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
LU501764B1 (en) 2022-03-31 2023-10-02 Leibniz Inst Fuer Naturstoff Forschung Und Infektionsbiologie E V Hans Knoell Inst Hki Gasdermin e expression in human t cells as a marker for proinflammatory t cell functions
AR129012A1 (es) * 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
EP4522600A1 (en) * 2022-05-13 2025-03-19 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
AU2023268557A1 (en) * 2022-05-13 2024-11-14 Ventus Therapeutics U.S., Inc. Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof
WO2023232917A1 (en) * 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Novel compounds
WO2024006559A1 (en) * 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
AU2023307538A1 (en) 2022-07-14 2025-01-23 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
CN119546599A (zh) * 2022-07-14 2025-02-28 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
JP2025523930A (ja) * 2022-07-21 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds
UY40374A (es) * 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
AR130151A1 (es) * 2022-08-10 2024-11-06 Takeda Pharmaceuticals Co Compuesto heterocíclico
KR20240022938A (ko) 2022-08-12 2024-02-20 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
PE20251293A1 (es) 2022-09-23 2025-05-14 Merck Sharp And Dohme Llc Derivados de ftalazina utiles como inhibidores de la proteina receptora 3 similar a nod
EP4610258A1 (en) 2022-10-26 2025-09-03 Tenvie Therapeutics, Inc. Fused pyridazine derivative
EP4612150A1 (en) * 2022-10-31 2025-09-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024097598A1 (en) * 2022-11-02 2024-05-10 Merck Sharp & Dohme Llc Triazines useful as inhibitors of nod-like receptor protein 3
WO2024094150A1 (en) * 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
CN121045190A (zh) * 2022-11-04 2025-12-02 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2024099993A1 (en) * 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
IL319009A (en) * 2022-11-09 2025-04-01 Hoffmann La Roche Triazinone derivatives as NLRP3 inhibitors
JP2025539252A (ja) * 2022-11-09 2025-12-04 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
EP4630417A1 (en) * 2022-12-07 2025-10-15 F. Hoffmann-La Roche AG Novel compounds as modulators of nlrp3 inhibition
KR20250137593A (ko) * 2022-12-23 2025-09-18 뉴모라 테라퓨틱스, 인코포레이티드 Nlrp3 인플라마솜의 조정제 및 관련 생성물 및 방법
TW202432558A (zh) * 2022-12-27 2024-08-16 大陸商正大天晴藥業集團股份有限公司 一種噠嗪稠芳環化合物及其用途
KR20250162767A (ko) 2022-12-28 2025-11-19 아스트라제네카 아베 Nlrp3 인플라마좀 억제제의 결정질 형태, 화학 공정 및 화학적 화합물
WO2024140824A1 (zh) * 2022-12-28 2024-07-04 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
UY40587A (es) 2022-12-28 2024-07-31 Astrazeneca Ab Inhibidores del inflamasoma nlrp3
AU2024206808A1 (en) * 2023-01-03 2025-07-17 Kodiak Sciences Inc. Organic compounds as nlrp3 inhibitors
WO2024148148A1 (en) * 2023-01-04 2024-07-11 The Trustees Of Columbia University In The City Of New York Pyridazine based small molecule inhibitor of cognitive impairment
EP4656635A1 (en) 2023-01-24 2025-12-03 Daiichi Sankyo Company, Limited Substituted benzene compound
WO2024158941A2 (en) * 2023-01-27 2024-08-02 Mwyngil Therapeutics, Inc. Inhibitors of nlrp3
AU2024214354A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv PYRROLO[1,2-d][1,2,4]TRIAZINES AND PYRAZOLO[1,5-d] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS
CN120981462A (zh) 2023-01-31 2025-11-18 詹森药业有限公司 咪唑并[1,2-d][1,2,4]三嗪作为NLRP3抑制剂
KR20250152598A (ko) 2023-01-31 2025-10-23 얀센 파마슈티카 엔브이 Nlrp3 억제제로서의 2-(피리다진-3-일)-5-(트라이플루오로메틸)페놀
WO2024160694A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
KR20250152069A (ko) 2023-01-31 2025-10-22 얀센 파마슈티카 엔브이 Nlrp3 억제제로서의 피리딘-2(1h)-온 및 피리미딘-4(3h)-온
CN120500485A (zh) 2023-02-14 2025-08-15 深圳众格生物科技有限公司 一种抑制nlrp3的化合物及制备方法和应用
WO2024169858A1 (zh) * 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
TW202502344A (zh) 2023-06-02 2025-01-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環
WO2025026252A1 (en) * 2023-08-02 2025-02-06 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
CN119462517A (zh) * 2023-08-11 2025-02-18 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2025046419A1 (ko) 2023-08-25 2025-03-06 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2025128777A1 (en) 2023-12-14 2025-06-19 Merck Sharp & Dohme Llc Indazole derivatives useful as inhibitors of nod-like receptor protein 3
US20250223290A1 (en) 2023-12-14 2025-07-10 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2025229146A1 (en) * 2024-05-02 2025-11-06 Sanofi Crystalline form of a pyridazine nlrp3 inhibitor
WO2025232839A1 (en) * 2024-05-09 2025-11-13 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2025252163A1 (zh) * 2024-06-07 2025-12-11 康百达（四川）生物医药科技有限公司 一种哒嗪并环衍生物及其在医药上的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510997A1 (fr) 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
FR2663326B2 (fr) 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010128152A1 (en) 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
WO2011048148A2 (en) 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
BR122014012788B1 (pt) 2010-06-23 2022-04-19 Hanmi Science Co., Ltd Derivados de pirimidina fundidos, seus usos, e composição farmacêutica para inibição da atividade de tirosina quinase
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Ｂｔｋ 억제제의 베실레이트 염
US8835472B2 (en) * 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
KR20190011343A (ko) 2011-06-10 2019-02-01 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
RU2615999C2 (ru) 2011-11-29 2017-04-12 Оно Фармасьютикал Ко., Лтд. Гидрохлорид производного пуринона
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP3181567B9 (en) 2012-09-10 2025-09-24 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
SG11201503697TA (en) 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
DK2989106T3 (en) 2013-04-25 2017-03-20 Beigene Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
TN2016000143A1 (en) 2013-11-05 2017-10-06 Novartis Ag Compositions and methods for modulating farnesoid x receptors.
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CA2931431A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
CN105829286B (zh) 2013-12-20 2019-05-31 诺华股份有限公司 作为lta4h抑制剂的杂芳基丁酸衍生物
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
NZ725044A (en) 2014-05-13 2019-03-29 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN103965169A (zh) 2014-05-30 2014-08-06 彭正中 一种化合物及其制备方法与用途
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
LT3209656T (lt) 2014-10-24 2020-07-27 Bristol-Myers Squibb Company Indolo karboksamidai - junginiai, naudingi kaip kinazės inhibitoriai
ES2846776T3 (es) 2014-12-24 2021-07-29 Principia Biopharma Inc Dosificación específica del sitio de un inhibidor de BTK
AU2016209321B2 (en) 2015-01-20 2019-05-09 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
US20180008629A1 (en) 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
JP6884102B2 (ja) * 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
PT3259253T (pt) 2015-02-16 2020-03-11 Univ Queensland Sulfonilureias e compostos relacionados e uso dos mesmos
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
PH12021551681A1 (en) 2015-06-03 2023-08-23 Prinicipia Biopharma Inc Tyrosine kinase inhibitors
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
TW202510883A (zh) 2015-11-04 2025-03-16 德商默克專利有限公司 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法
EA201800367A1 (ru) * 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10626116B2 (en) 2016-01-05 2020-04-21 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of BTK kinase inhibitor and preparation method thereof
US10787433B2 (en) 2016-01-15 2020-09-29 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2018232039A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
HUE057414T2 (hu) 2017-07-07 2022-05-28 Inflazome Ltd Új szulfonamid karboxamid vegyületek
WO2019014402A1 (en) 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. MODULATORS OF NLRP3
KR102636383B1 (ko) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
BR112020003014A2 (pt) * 2017-08-15 2020-07-28 Inflazome Limited sulfonilureias e sulfoniltioureias como inibidores de vnlrp3
EP3688187A4 (en) 2017-09-25 2021-09-29 Skyhawk Therapeutics, Inc. PROCEDURES AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPICE MODULATORS
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019199972A1 (en) 2018-04-10 2019-10-17 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
CN112771038B (zh) 2018-04-26 2024-09-24 奥里吉恩发现科技有限公司 作为smarca2/4降解剂的哒嗪衍生物
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
AR121669A1 (es) 2020-03-27 2022-06-29 Astellas Pharma Inc Compuesto de piridazina sustituida
US20240391895A1 (en) 2020-12-25 2024-11-28 Tuojie Biotech (Shanghai) Co., Ltd. Pyridazine-containing compound and medicinal use thereof
CN116867769A (zh) 2021-02-08 2023-10-10 南京明德新药研发有限公司 取代的哒嗪苯酚类衍生物

Also Published As

Publication number Publication date
US20200361899A1 (en) 2020-11-19
US11208399B2 (en) 2021-12-28
JOP20210307A1 (ar) 2023-01-30
CR20210552A (es) 2021-11-26
AU2020277738B2 (en) 2023-03-02
JP2025004014A (ja) 2025-01-14
KR20220008887A (ko) 2022-01-21
JP7558975B2 (ja) 2024-10-01
CU20210094A7 (es) 2022-06-06
US20250270188A1 (en) 2025-08-28
TWI874398B (zh) 2025-03-01
WO2020234715A1 (en) 2020-11-26
CA3138226A1 (en) 2020-11-26
DOP2021000228A (es) 2021-12-15
CO2021015030A2 (es) 2021-11-30
US11254653B2 (en) 2022-02-22
PE20220133A1 (es) 2022-01-27
IL287042A (en) 2021-12-01
SA521430853B1 (ar) 2024-08-05
CN119732956A (zh) 2025-04-01
SG11202111029PA (en) 2021-12-30
CN113784957A (zh) 2021-12-10
MX2021013941A (es) 2022-03-11
TW202110809A (zh) 2021-03-16
MY206068A (en) 2024-11-27
CL2021003012A1 (es) 2022-09-09
UY38687A (es) 2023-05-15
PH12021552885A1 (en) 2022-07-25
JP2022532354A (ja) 2022-07-14
AR119731A1 (es) 2022-01-05
ZA202107444B (en) 2024-11-27
US20220251067A1 (en) 2022-08-11
US20200361898A1 (en) 2020-11-19
US12139471B2 (en) 2024-11-12
BR112021022796A2 (pt) 2022-04-12
CN113784957B (zh) 2025-02-28
IL287042B1 (en) 2024-10-01
EP3969441A1 (en) 2022-03-23
AU2020277738A1 (en) 2021-11-18
IL287042B2 (en) 2025-02-01

Similar Documents

Publication Publication Date Title
ECSP21080740A (es) Inhibidores del inflamasoma nlrp3
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
CL2024000552A1 (es) Inhibidores de nlrp3
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CL2025000285A1 (es) Inhibidores de inflamasoma nlrp3
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CO2024011162A2 (es) Inhibidores de nlrp3
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
CO2021001174A2 (es) Inhibidores de ckd8/19
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados
AR134411A1 (es) Compuestos de uracilo